This report covers advances in capillary electrophoresis (CE) from January 2018 through September 2019. A summary of the literature during this time period is insightful. A search performed using the SciFinder Scholar database for journal reports (limited to English) using the term capillary electrophoresis returned approximately 1,800 publications.
Further analysis of this list provided a snapshot of activity in biomolecular research. Classes of biomolecules most frequently associated with CE publications were proteins, drugs, DNA and metabolites. Another measure of the impact of CE is the translation of this technology into society.
A search of patent activity illustrating this process of CE technology transfer returned 346 patents published in all languages, with a substantial contribution reported only in Chinese (198 patents) or English (98 patents).
Established applications of CE continued to serve as the gold standard for molecular separations providing analytical assays, enantiomeric resolution and DNA analyses for human identification. The versatility of CE for biological systems is exemplified by the rise of the technique in several areas. Metabolomics research involving measurements of large sets of molecules with subtle structural differences benefits from rapid separations achieved with high peak capacity and automated instruments.
Single cell and sub-cellular analyses continue to progress in CE because of the size compatibility of the technique with the sample. Other examples of areas utilizing CE that are accelerating include portable and printable instrumentation, affinity interaction, as well as proteomics. As an established analytical tool, CE instrumentation and methods have been designed to be accessible and easily adopted by researchers with expertise in areas beyond the field of separations.
Sulforhodamine 101 |
80101 |
Biotium |
500MG |
EUR 236 |
Description: Minimum order quantity: 1 unit of 500MG |
Trap 101 |
B7084-10 |
ApexBio |
10 mg |
EUR 373 |
Trap 101 |
B7084-50 |
ApexBio |
50 mg |
EUR 1363 |
UFP-101 |
B5128-1 |
ApexBio |
1 mg |
EUR 583 |
LOXO-101 |
B6176-100 |
ApexBio |
100 mg |
EUR 696 |
Description: IC50: low nanomolar range for inhibition of all TRK family membersLOXO-101 is a tropomyosin receptor kinases (TRK) inhibitor.The TRK family of neurotrophin receptors and their neurotrophin ligands regulate neuron growth, differentiation and survival. |
LOXO-101 |
B6176-25 |
ApexBio |
25 mg |
EUR 290 |
Description: IC50: low nanomolar range for inhibition of all TRK family membersLOXO-101 is a tropomyosin receptor kinases (TRK) inhibitor.The TRK family of neurotrophin receptors and their neurotrophin ligands regulate neuron growth, differentiation and survival. |
LOXO-101 |
B6176-5 |
ApexBio |
5 mg |
EUR 128 |
Description: IC50: low nanomolar range for inhibition of all TRK family membersLOXO-101 is a tropomyosin receptor kinases (TRK) inhibitor.The TRK family of neurotrophin receptors and their neurotrophin ligands regulate neuron growth, differentiation and survival. |
GlyH-101 |
B1087-10 |
ApexBio |
10 mg |
EUR 195 |
Description: GlyH-101 is a cell-permeable glycinyl hydrazone compound that blocks CFTR with Ki of 1.4 uM. |
GlyH-101 |
B1087-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 148 |
Description: GlyH-101 is a cell-permeable glycinyl hydrazone compound that blocks CFTR with Ki of 1.4 uM. |
GlyH-101 |
B1087-50 |
ApexBio |
50 mg |
EUR 659 |
Description: GlyH-101 is a cell-permeable glycinyl hydrazone compound that blocks CFTR with Ki of 1.4 uM. |
ARP 101 |
A4433-5 |
ApexBio |
5 mg |
EUR 334 |
Description: ARP 101 is a selective MMP-2 inhibitor with IC50 value of 0.81nM. |
AT-101 |
A3196-10 |
ApexBio |
10 mg |
EUR 171 |
Description: AT101, a natural product from cottonseed with a BH3-mimetic structure, was identified as a small molecule inhibitor of Bcl-2/Bcl-xL/Mcl-1 that potently induces apoptosis in various cancer cell lines [1]. |
AT-101 |
A3196-50 |
ApexBio |
50 mg |
EUR 432 |
Description: AT101, a natural product from cottonseed with a BH3-mimetic structure, was identified as a small molecule inhibitor of Bcl-2/Bcl-xL/Mcl-1 that potently induces apoptosis in various cancer cell lines [1]. |
Sulforhodamine 101 |
B7762-100 |
ApexBio |
100 mg |
EUR 137 |
Sulforhodamine 101 |
B7762-250 |
ApexBio |
250 mg |
EUR 257 |
Sulforhodamine 101 |
B7762-500 |
ApexBio |
500 mg |
EUR 390 |
AS 101 |
B7830-5 |
ApexBio |
5 mg |
EUR 171 |
Description: Ammonium tri-chloro(dioxoethylene-O,O?-)tellurate (AS-101), an anti?IL-10 compound, is a nontoxic immunomodulator.AS101 (0.43222.5 ?g/ml) decreased IL-10 production in a dose-dependent manner. |
CUDC-101 |
A4092-10 |
ApexBio |
10 mg |
EUR 137 |
Description: CUDC-101 is a multitargeted inhibitor of histone deacetylase. It is designed to directly inhibit epidermal growth factor receptor (EGFR) and HER2 as well as class I and class II HDACs. |
CUDC-101 |
A4092-200 |
ApexBio |
200 mg |
EUR 943 |
Description: CUDC-101 is a multitargeted inhibitor of histone deacetylase. It is designed to directly inhibit epidermal growth factor receptor (EGFR) and HER2 as well as class I and class II HDACs. |
CUDC-101 |
A4092-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 158 |
Description: CUDC-101 is a multitargeted inhibitor of histone deacetylase. It is designed to directly inhibit epidermal growth factor receptor (EGFR) and HER2 as well as class I and class II HDACs. |
CUDC-101 |
A4092-50 |
ApexBio |
50 mg |
EUR 386 |
Description: CUDC-101 is a multitargeted inhibitor of histone deacetylase. It is designed to directly inhibit epidermal growth factor receptor (EGFR) and HER2 as well as class I and class II HDACs. |
CUDC-101 |
A4092-S |
ApexBio |
Evaluation Sample |
EUR 81 |
Description: CUDC-101 is a multitargeted inhibitor of histone deacetylase. It is designed to directly inhibit epidermal growth factor receptor (EGFR) and HER2 as well as class I and class II HDACs. |
UCF 101 |
C4437-10 |
ApexBio |
10 mg |
EUR 186 |
Description: IC50: 9.5 ?MUCF 101 is an inhibitor of Omi/HtrA2. Omi/HtrA2, a mitochondria serine protease with close homology to bacterial HtrA chaperones, is released from the mitochondria in response to apoptotic stimuli. |
UCF 101 |
C4437-25 |
ApexBio |
25 mg |
EUR 354 |
Description: IC50: 9.5 ?MUCF 101 is an inhibitor of Omi/HtrA2. Omi/HtrA2, a mitochondria serine protease with close homology to bacterial HtrA chaperones, is released from the mitochondria in response to apoptotic stimuli. |
UCF 101 |
C4437-5 |
ApexBio |
5 mg |
EUR 145 |
Description: IC50: 9.5 ?MUCF 101 is an inhibitor of Omi/HtrA2. Omi/HtrA2, a mitochondria serine protease with close homology to bacterial HtrA chaperones, is released from the mitochondria in response to apoptotic stimuli. |
miRZip-101 anti-miR-101 microRNA construct |
MZIP101-PA-1 |
SBI |
Bacterial Streak |
EUR 684 |
|
KHS 101 hydrochloride |
B7717-10 |
ApexBio |
10 mg |
EUR 318 |
KHS 101 hydrochloride |
B7717-50 |
ApexBio |
50 mg |
EUR 1162 |
Generally, publications including CE measurements either outline innovations in the technique or they are compelling applications of a mature analytical approach. The goal of this review, which is limited to 180 citations, is to communicate an overview of recent developments, focusing on reports describing advances to the technology. Although publications that utilize CE are found in a diverse set of periodicals, the reports included in this review are from journals that are popular in the field of analytically-based separation chemistry.